Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
CHAMPION-1
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
- NCT01677858 ↗
- Completed
- Amgen
- Focused
We haven't built an HCP commentary report on CHAMPION-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CHAMPION-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib; Dexamethasone
- Arms
- Carfilzomib · Experimental
- Enrollment
- 116
- Primary outcomes
- Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)
- Overall Response Rate (ORR)
- Sponsor
- Amgen
- Start
- Jul 4, 2012
- Primary completion
- Jul 22, 2016
- Results posted
- Yes
- Registry record
- NCT01677858 · updated Sep 23, 2022
Publications
linked from the registry- Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MV. Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020 May;9(9):2989-2996. doi: 10.1002/cam4.2945. Epub 2020 Feb 28. PubMed 32108443
- Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12. PubMed 27207788